Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.
Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.
Charles River Laboratories is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.
Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
Belgium's Galapagos NV says that GlaxoSmithKline is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis.
A day after AbbVie unveiled an $840 million tie-up to develop a new anti-inflammatory therapy, the pharma company is continuing its deal spree today with a $405 million discovery pact on cystic fibrosis with Belgium's Galapagos.
The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease.
Swiss drug giant Roche has exited an alliance with Belgium-based biotech Galapagos focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases.
The cash deal delivers AP214, in development to prevent acute kidney injury associated with major cardiac surgery.
Belgian biotech Galapagos has made progress in its alliance with the Janssen Pharmaceutica unit of healthcare giant Johnson & Johnson, revealing today that it has identified the first preclinical candidate in the collaboration.